Literature DB >> 23800509

Echo-Doppler assessment of arterial stiffness in pediatric patients with Kawasaki disease.

Abdullah AlHuzaimi1, Yahya Al Mashham, James E Potts, Astrid M De Souza, George G S Sandor.   

Abstract

BACKGROUND: There is growing evidence to suggest increased arterial stiffness in patients with a history of Kawasaki disease (KD). Pulse-wave velocity (PWV) is the most validated measure of arterial stiffness. The aim of this study was to determine if aortic PWV is increased in children with KD.
METHODS: This was a retrospective cohort study. The study cohort was composed of 42 patients with KD (mean age, 9.7 ± 2.0 years) and 44 age-matched control subjects. The primary measure was aortic PWV. Secondary measures included characteristic impedance (Zc), input impedance (Zi), elastic pressure-strain modulus (Ep), and β stiffness index and the following measures of left ventricular size and function: end-diastolic and end-systolic dimensions, wall thickness in diastole and systole, mass, shortening and ejection fractions, mean velocity of circumferential fiber shortening, and stress at peak systole. The appropriate measures were indexed to body surface area. The aortic stiffness and impedance indexes were derived using an echocardiography-Doppler method.
RESULTS: Height, weight, body mass index, and body surface area were similar between the groups. PWV was higher in patients with KD compared with controls (495 vs 370 cm/sec, P = .0008). Zc, Ep, and β stiffness index were higher in patients with KD, but the difference was not statistically significant. Left ventricular dimensions were all within normal limits, with no differences between the groups. Patients with KD had lower stress at peak systole compared with controls (55 vs 64 g/cm(2), P = .01). There was a significant association between the length of time between the initial diagnosis and testing with PWV (r = 0.32, P = .04) and Zi (r = -0.38, P = .01) in patients with KD. There was no significant association between the arterial stiffness indexes (PWV, Zi, Zc, Ep, and β stiffness index) and length of fever, age at KD diagnosis, or heart rate. Logistic regression analysis revealed no association between coronary artery lesion classification and length of fever, day of illness at first treatment, age at KD diagnosis, or any of the arterial stiffness indexes. In the control group, there were significant associations between age and heart rate (r = -0.48, P = .001), Zi (r = -0.55, P < .0001), Zc (r = -0.66, P < .0001), and β stiffness index (r = -0.31, P = .04). There was an association between heart rate and Zc (r = 0.44, P = .003) but no association between heart rate and PWV, Zi, Ep, or β stiffness index.
CONCLUSIONS: Arterial stiffness was increased in children with KD. There was no association between acute-phase KD coronary involvement and PWV. This implies that patients with KD may be at increased cardiovascular risk in the future.
Copyright © 2013 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  AOcsa; AOd; AOflow; AOs; Aortic annular cross-sectional area; BPd; BPs; CAL; Characteristic impedance; Coronary artery lesion; Diastolic blood pressure; Diastolic posterior wall thickness; EF; Echocardiography Doppler; Ejection fraction; Elastic pressure-strain modulus; End-diastolic aortic dimension; End-systolic aortic dimension; Ep; Input impedance; KD; Kawasaki disease; LV; LVEDD; LVESD; LVMi; Left ventricular; Left ventricular end-diastolic dimension; Left ventricular end-systolic dimension; Left ventricular mass index; MVCFc; Mean velocity of circumferential fiber shortening; PP; PWV; PWd; PWs; Peak aortic flow; Pulse pressure; Pulse-wave velocity; SF; Shortening fraction; Stress at peak systole; Systolic blood pressure; Systolic posterior wall thickness; TT; Transit time; Vascular function; Zc; Zi; σps

Mesh:

Year:  2013        PMID: 23800509     DOI: 10.1016/j.echo.2013.05.015

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  8 in total

1.  miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Authors:  Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy
Journal:  Circ Res       Date:  2016-12-06       Impact factor: 17.367

Review 2.  Kawasaki Disease: Pathology, Risks, and Management.

Authors:  Mitsuru Seki; Takaomi Minami
Journal:  Vasc Health Risk Manag       Date:  2022-06-10

Review 3.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

4.  Aortic stiffness studies in children with Kawasaki disease: preliminary results from a follow-up study from North India.

Authors:  Anand Gupta; Surjit Singh; Anju Gupta; Deepti Suri; Manojkumar Rohit
Journal:  Rheumatol Int       Date:  2014-04-03       Impact factor: 2.631

Review 5.  Vascular health late after Kawasaki disease: implications for accelerated atherosclerosis.

Authors:  Yiu-Fai Cheung
Journal:  Korean J Pediatr       Date:  2014-11-30

6.  The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease.

Authors:  Takamichi Ishikawa; Keigo Seki
Journal:  BMC Cardiovasc Disord       Date:  2018-02-09       Impact factor: 2.298

7.  Long-Term Prognosis for Patients with Kawasaki Disease Complicated by Large Coronary Aneurysm (diameter ≥6 mm).

Authors:  Ji Seok Bang; Gi Beom Kim; Bo Sang Kwon; Mi Kyung Song; Hyo Soon An; Young Whan Song; Eun Jung Bae; Chung Il Noh
Journal:  Korean Circ J       Date:  2017-07-27       Impact factor: 3.243

Review 8.  The Progress of Advanced Ultrasonography in Assessing Aortic Stiffness and the Application Discrepancy between Humans and Rodents.

Authors:  Wenqian Wu; Mingxing Xie; Hongyu Qiu
Journal:  Diagnostics (Basel)       Date:  2021-03-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.